ANDA BIOPHARMA

ANDA BIOPHARMA was founded in December 2018 with a registered capital of 13.6 million yuan. Headquartered in Shenzhen, the company currently has branches in Shanghai, Tianjin, Shijiazhuang, Guangxi, and other places. Under the leadership of a senior researcher from the Chinese Academy of Sciences, ANDA BIOPHARMA integrates top talents and technologies in the fields of tumor genomics, immunology, and vaccinology to focus on the development of novel personalized therapeutic vaccines for cancer. After four years of efforts, ANDA BIOPHARMA has established a comprehensive system for personalized tumor mutation identification, neoantigen prediction and vaccine design, as well as immunogenicity and safety evaluation, and is currently undergoing an IND application. In April 2018, clinical trial research was conducted at Changhai Hospital, initiating a clinical study on cancer immunotherapy targeting pancreatic ductal adenocarcinoma.